BioCentury
ARTICLE | Finance

Ebb & Flow Focus

June 14, 2004 7:00 AM UTC

More than three years after the last biotech IPO in Germany, there's a glimmer of light at the end of the tunnel, as companies are starting to talk about the possibility of going public in Frankfurt.

The talk was boosted last week when Jerini AG (Berlin, Germany) raised E31 million ($38 million) in Germany's second largest venture round ever. The cancer, autoimmune and inflammation company is preparing for an IPO, probably within the next 12 months. ...